Calcium Channel Blockers and Alzheimer's Disease: Potential Relevance in Treatment Strategies of Metabolic Syndrome

William V. Goodison, Vincenza Frisardi, Patrick G. Kehoe*

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)

22 Citations (Scopus)

Abstract

Midlife hypertension is a risk factor for late onset Alzheimer's disease (AD) and it is one of the components of metabolic syndrome (MetS). Observational studies and some cardiovascular disease-related clinical trials suggest that antihypertensive treatment reduced the incidence and progression of AD. Calcium channel blockers (CCBs), one of the more commonly used treatments for hypertension, target voltage-gated calcium channels (VGCCs) which are found on neurons in the brain where calcium regulation is very important in both learning and memory. Amyloid-β (Aβ) peptide, one of the main pathological hallmarks of AD, causes increases to intracellular calcium via VGCCs, which in turn leads to further increases in Aβ production. Memantine, a current treatment used in AD, exerts some of its beneficial effects by blocking calcium entry into neurons. We explore the possibility of whether CCBs acting in the brain may delay the onset and progression of AD and thus may inform treatment regimes in people with MetS.
Translated title of the contributionCalcium Channel Blockers and Alzheimer's Disease: Potential Relevance in Treatment Strategies of Metabolic Syndrome
Original languageEnglish
Pages (from-to)S269-S282
Number of pages14
JournalJournal of Alzheimer's Disease
Volume30 Suppl 2
DOIs
Publication statusPublished - Feb 2012

Keywords

  • calcium
  • cognitive decline
  • ANGIOTENSIN-CONVERTING ENZYME
  • PROSPECTIVE COHORT
  • AMYLOID-BETA
  • A-BETA OLIGOMERS
  • BLOOD-PRESSURE
  • treatment
  • Alzheimer's disease
  • blood brain barrier
  • dementia
  • voltage-gated calcium channel
  • CARDIOVASCULAR RISK
  • CORTICAL-NEURONS
  • CULTURED HIPPOCAMPAL-NEURONS
  • COGNITIVE DECLINE
  • metabolic syndrome
  • hypertension
  • amyloid-beta
  • calcium channel blocker
  • INSULIN-DEGRADING ENZYME

Fingerprint Dive into the research topics of 'Calcium Channel Blockers and Alzheimer's Disease: Potential Relevance in Treatment Strategies of Metabolic Syndrome'. Together they form a unique fingerprint.

Cite this